期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2型糖尿病治疗新药——利拉鲁肽 被引量：7

下载PDF
导出
摘要 本文介绍了降糖新药人胰高糖素样肽-1(GLP-1)类似物利拉鲁肽的药物动力学及其在降糖和β细胞功能保护等方面的重要作用。
作者 吴世斌 赵梅 温传彬 姚松
机构地区 江苏万邦生化医药股份有限公司
出处 《中国生化药物杂志》 CAS CSCD 北大核心 2012年第2期210-212,共3页 Chinese Journal of Biochemical Pharmaceutics
关键词 利拉鲁肽 药物动力学 降糖 β细胞保护 安全性
分类号 R977.15 [医药卫生—药品]
  • 相关文献

参考文献11

二级参考文献38

  • 1傅勇,李蓬秋.GLP-1抗糖尿病作用研究进展[J].实用糖尿病杂志,2007,3(3):53-55. 被引量：8
  • 2Drucker D, Nouck M. The incretin system: glucagon - like peptide - 1 receptor agonistes and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J]. Lancet ,2006, 368 : 1696 - 1699.
  • 3Mudaliar S, Henry RR. Incretin therapies:effects beyond glycemic control [J]. Am Med,2009, 122 ( suppl ):S25 - S36.
  • 4Russell- Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once - daily human GLP - 1 analogue [J]. Mol Cell Endocrinol,2009,297(2) : 137 - 140.
  • 5Joshua J. Differdntial chemistry (structure), mechanism of action, and pharmacology of GLP - 1 receptor agonists and DPP - 4 inhibitors [ J ]. Am Pharm Assoe, 2009,49 (suppl 1 ) : S16 - S29.
  • 6Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once - daily human GLP - 1 analogue, improves pancreatic B - cell function and arginine - stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus [J]. Diabet Med,2008,25(2) : 152- 156.
  • 7Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride montherapy for type 2 diabetes ( LEAD - 3 Mono) : a randomised, 52 -week, phase 3, double - blind, parallel - treatment trial [ J ]. Lancet, 2009,373 :473 -481.
  • 8Marre M, Shaw J, Brandle M, et al. Liraglutide, a once -daily human GLP - 1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes ( LEAD - 1 SU) [J]. Diabet Med,2009,26(3) : 268 -278.
  • 9Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes) - 2 study [ J]. Diabetes Care,2009,32( 1 ) : 84 - 90,.
  • 10Zinman B, Gefich J, Buse JB, et al. Efficacy and safety of the human glucagon - like peptide - 1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diaetes ( LEAD - 4 Met + TZD) [ J ]. Diabetes Care, 2009,32 (7) : 1224 - 1230.

共引文献40

同被引文献89

  • 1刘素芳,陈屏,许继田,王清勇,姚运纬.GLP-1(7-36)NH_2的促胰岛素分泌作用和胞内cAMP浓度改变与胰岛素mRNA表达[J].中国应用生理学杂志,2004,20(3):217-218. 被引量：6
  • 2赵水平.他汀类药物降脂疗效个体差异及其机制[J].中南药学,2003,1(4):195-196. 被引量：3
  • 3王建生,张庆军,金水高.我国高血压和糖尿病的疾病负担分析[J].公共卫生与预防医学,2007,18(3):27-30. 被引量：44
  • 4第四军医大学生理学系.胰岛素诞生[-EB/OL].[2005-10-07].http:∥jcbphysiology.fmmu.edu.cn/yds/history/faxian01.htm.
  • 5第四军医大学生理学系.糖尿病的历史和发展FEB/OL].[2005-10-07].http:∥jcbphysiology.fmmu.edu.cn/yds/application/xuetang01.htm.
  • 6Leah. Medicines in Development For Diabetes [DB/ OL]. [2013-02-05]. http: //phrma. org/sites/de- fault/files/1869/diabetes2012, pdf.
  • 7Leah. Overview.. new medicines in development for diabetes [DB/OL ]. I- 2013-02-05 ]. http: //phrma. org/sites/default/files/1869/12- 535phrmaoverviewdiabetesl109. pdf.
  • 8Berggren E K,Boggess K A,Stuebe A M,et al. Na- tional Diabetes Data Group vs Carpenter-Coustan criteria to diagnose gestational diabetes [J]. Am J Obstet Gynecol, 2011,205(3) :253. el-253, e7.
  • 9Pharmaceutical Research and Manufacturers of America. Two paths to better controlling diabetes [EB/OL]. [2012-11-13]. http ://phrma. org/media/ releases/innovation-adherence -two -paths-better-con- trolling-diabetes.
  • 10Pharmaceutical Research and Manufacturers of America. New report shows over 220 new medicines in development for diabetes[EB/OL]. [2012-11-13]. http: // www. innovation, org/index, cfm/Future- ~flnnovation/NewMedicinesinDevelopment/Dia_ betes.

引证文献7

二级引证文献48

中国生化药物杂志
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部